Key facts
- It has raised $6.5M; the latest was Early Stage VC ($40.0M) in Jan 2026.
- Notable investors include Rosalind Franklin University of Medicine and Science.
- 32 Biosciences has filed 1 Form D with the SEC, most recently May 2024 ($160K sold to 3 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for 32 Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for 32 Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About 32 Biosciences
Operator of a biosciences company intended to transform gut microbiome science into diagnostic and therapeutic bioscience. The company generates data to develop microbiome-based interventions that aim to treat and prevent human disease by diagnosing and treating dysbiosis, and also offers clinically useful, validated precision tools to analyze and correct dysbiosis, enabling users to get evidence to treat and prevent human disease by diagnosing and treating dysbiosis.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2023
- Website
- 32biosciences.com/
- Ownership
- Privately Held (backing)
32 Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in 32 Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on 32 Biosciences in its N-PORT filings yet. We sweep new filings monthly.